ArticleAlzheimer's research & therapy2026
Palmitoylation of death receptor p75
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although protein palmitoylation has been associated with Alzheimer’s Disease (AD), it remains unclear whether or how palmitoylation of specific proteins contributes to any of the pathological features of AD. The p75 neurotrophin receptor (p75NTR) contributes to AD progression by regulating the intracellular trafficking and amyloidogenic processing of amyloid precursor protein (APP). p75NTR is palmitoylated at a juxtamembrane cysteine but it is currently unknown whether this has any effect on its role in AD. Here, we report that 5xFAD mice, an animal model of AD, expressing a palmitoylation-deficient mutant of p75NTR (p75C281A) display significantly attenuated neuropathology and cognitive deficits. Mechanistically, p75C281A showed enhanced internalization, trafficking to Rab5/Rab7 endosomes and lysosomal-mediated degradation. In mutant p75C281A neurons, APP displayed accelerated co-internalization with p75NTR, increased trafficking to late endosomes and lysosome, and enhanced degradation, thereby limiting neuronal Aβ production. Interestingly, the brain of 5xFAD mice shows increased levels of p75NTR palmitoylation. These results indicate that palmitoylation of p75NTR enhances its stability and, indirectly, that of APP by reducing their trafficking to the lysosome, resulting in increased Aβ accumulation and neuropathology in the AD brain. Selective inhibitors of p75NTR palmitoylation may find applications in the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.